Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCEH1 | Q6PIU2 | 13/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3267487 | 0.84 | ERN1 (0.47) | RAB9ALMNANPC1ERN1ALDH1A1 | |
| SCHEMBL26120834 | 0.80 | ELANE (0.46) | RAB9ANPC1ERN1ALDH1A1KMT2A | |
| SCHEMBL3269014 | 0.77 | ERN1 (0.55) | LMNAERN1ALDH1A1 | |
| Naphthalen-2-Yl Dimethylcarbamate SCHEMBL31152493 | 0.75 | NCEH1 (0.70) | NCEH1RAB9ALMNAPKMALDH1A1 | |
| Naphthalen-2-Yl Dimethylcarbamate SCHEMBL16005596 | 0.75 | NCEH1 (0.70) | NCEH1RAB9ALMNAPKMALDH1A1 | |
| SCHEMBL3267963 | 0.73 | ERN1 (0.46) | ERN1ALDH1A1 | |
| SCHEMBL13886669 | 0.72 | KMT2A (0.49) | RAB9ALMNANPC1TSHRERN1 | |
| SCHEMBL13594500 | 0.72 | RAB9A (0.54) | NCEH1RAB9ALMNAPKMNPC1 | |
| SCHEMBL16965580 | 0.71 | NCEH1 (0.77) | NCEH1RAB9ALMNAPKMNPC1 | |
| SCHEMBL29728565 | 0.71 | NCEH1 (0.77) | NCEH1RAB9ALMNAPKMNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1914229-B1 | NOVEL CERCOSPORAMIDE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-06-16 | — | — | EP | disclosed |
| US-20090036492-A1 | Novel Cercosporamide Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1914229-A1 | NOVEL CERCOSPORAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036492-A1 | Novel Cercosporamide Derivative | GPR119, CBR3, SLC5A2 | NCEH1 41/4885RAB9A 1054/4885LMNA 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.